Research has come a long way, but RA is still a complex disease to treat
Up to 25% of RA patients in industrialised countries will not achieve low disease activity on biologic or synthetic DMARDs.1 While many patients will achieve ACR20, over 75% of MTX-IR or TNF-IR patients may not achieve low disease activity (ie, ACR 70) on targeted therapies.1
According to treat-to-target recommendations, the absence of remission or low disease activity requires a change in therapy.1 However, response to targeted therapies diminishes with every subsequent line of treatment.2
In RA, there is an increase in rates of serious infections from less than 1/1000 PYs in the healthy population to 5/1000 PYs in people with RA.3 Patients with RA also have an increased risk of cardiovascular comorbidities and mortality compared to the generalpopulation.4-6
References: 1. Aletaha D, Smolen JS. JAMA. 2018;320(13):1360-1372.
2. Rendas-Baum R, et al. Arthritis Res Ther. 2011;13(1):R25.
3. Ravanbod H, et al. J Immunol Infect Inflam Dis. 2017;2(3):1-9.
4. Crowson CS, et al. Am Heart J. 2013;166(4):622-628.e1.
5. Kaplan MJ. Rheum Dis Clin North Am. 2010;36(2): 405-426.
6. Aviña-Zubieta JA, et al. Arthritis Rheum. 2008;59(12):1690-1697.
The information contained in this website is directed exclusively to professionals authorised to prescribe or dispense medicinal products. Thus, the information contained in this website requires specialised training and scientific background for its correct interpretation.
By clicking “Continue” you acknowledge that you are a healthcare professional